NASDAQ:CYCC Cyclacel Pharmaceuticals Q1 2025 Earnings Report $0.28 +0.05 (+21.62%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.28 +0.00 (+0.54%) As of 04/25/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Cyclacel Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS -$0.29Beat/MissN/AOne Year Ago EPSN/ACyclacel Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$0.03 millionBeat/MissN/AYoY Revenue GrowthN/ACyclacel Pharmaceuticals Announcement DetailsQuarterQ1 2025Date5/7/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Cyclacel Pharmaceuticals Earnings HeadlinesCyclacel Pharmaceuticals files to sell 35.18M shares of common stock for holdersApril 27 at 3:30 PM | markets.businessinsider.comCyclacel Pharmaceuticals Stock Price, Quotes and Forecasts | NASDAQ:CYCC | BenzingaApril 27 at 2:19 AM | benzinga.comTrump’s Secret Social Security Plan?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 28, 2025 | Paradigm Press (Ad)Cyclacel Pharmaceuticals (NASDAQ:CYCC) Coverage Initiated at StockNews.comApril 26 at 2:39 AM | americanbankingnews.comStockNews.com Initiates Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)April 18, 2025 | americanbankingnews.comCyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business UpdateApril 2, 2025 | globenewswire.comSee More Cyclacel Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cyclacel Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cyclacel Pharmaceuticals and other key companies, straight to your email. Email Address About Cyclacel PharmaceuticalsCyclacel Pharmaceuticals (NASDAQ:CYCC), a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.View Cyclacel Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Upcoming Earnings AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025)Booking (4/29/2025)América Móvil (4/29/2025)Pfizer (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
